A Discussion With Experts on the Evolving Therapeutic Landscape in T-Cell Lymphomas: Focus on EZH1/2 Inhibitors

Get up to date on the optimal use of EZH1/2 inhibitors in PTCL with this expert-authored commentary plus downloadable slides and on-demand webcast from a live CCO symposium at ASCO 2022.

Share

Program Content

Activities

PTCL Current Options
PTCL: Current Options and Clinical Outcomes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2022

Expires: June 01, 2023

Anti-EZH1/2 Mechanisms
Mechanisms of Action of EZH1 and EZH2 and Anti-EZH1 and EZH2 Therapies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2022

Expires: June 01, 2023

Anti-EZH1/2 Evidence
Clinical Trial Evidence of the Use of Anti-EZH1/2 Therapies in PTCL and Managing Adverse Events
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2022

Expires: June 02, 2023

No activities added yet

Activities

EZH1/2 Inhibitors in PTCL
Rationale and Evidence for EZH1/2 Inhibitors in PTCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 08, 2022

Expires: August 07, 2023

Faculty

cover img faculity

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

cover img faculity

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

cover img faculity

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.